Click for best price
Postpemic Era Autoimmune Hepatitis Treatment Market Size, Share 2022
Summary
The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery.
2022 is a year of continuous recovery. Global supply chain disturbance, geopolitical tension, energy price fluctuation, local labor shortage and rising raw material prices will affect the resilience of economic recovery. The International Monetary Fund (IMF) predicts that the world economy will grow by 4.4% in 2022, of which the U.S. economy will grow by about 4%. Driven by China and India, Asia is expected to become the fastest growing region in the world in 2022. However, China's economic growth has slowed down. The 2022 government work report shows that the expected target of economic growth is set at about 5.5%.
According to research, China has set a growth rate of about 5.5%, which not only focuses on the speed of economic growth, but also anchors the quality of economic development. Scientific and technological innovation, economic and social digitization and green development will be the long-term goals of China's economic development. It is expected that in 2022, major economies such as the United States, Europe and China will introduce more favorable policies to drive the development of switching power supply industry.
(Post-pandemic Era)-Global Autoimmune Hepatitis Treatment Market Segment Research Report 2022?, which aims to sort out the development status and trends of the Autoimmune Hepatitis Treatment industry at home and abroad, estimate the overall market scale of the Autoimmune Hepatitis Treatment industry and the market share of major countries, Autoimmune Hepatitis Treatment industry, and study and judge the downstream market demand of Autoimmune Hepatitis Treatment through systematic research, Analyze the competition pattern of Autoimmune Hepatitis Treatment, so as to help solve the pain points of various stakeholders in Autoimmune Hepatitis Treatment industry. This industry research report combines desktop research, qualitative interviews with insiders or experts and other methods to strive for the objectivity and integrity of conclusions and data.
Regional Segmentation (Value; Revenue, USD Million, 2018-2028) of Autoimmune Hepatitis Treatment Market by Research Include
USA
Europe
China
Japan
India
Korea
Southeast Asia
Competitive Analysis; Who are the Major Players in Autoimmune Hepatitis Treatment Market?
Gilead Sciences, Inc.
Acorda Therapeutics, Inc.
Allergan & Novartis
Intercept Pharmaceuticals, Inc.
Hightidetx
Shire Plc.
NGM Biopharmaceuticals, Inc.
EA Pharma
BiomX
CymaBay Therapeutics
Conatus Pharmaceuticals, Inc.
Durect Corporation
Sirnaomics, Inc.
Shenzhen HighTide Biopharmaceuticals Ltd.
Major Type of Autoimmune Hepatitis Treatment Covered in Research report:
Table Product
Inject Product
Others
Application Segments Covered in Research Market
Hospital
Clinic
Others
For any other requirements, please feel free to contact us and we will provide you customized report.
| Report Attributes |
Report Details |
| Report Title |
(Post-pandemic Era)-Global Autoimmune Hepatitis Treatment Market Segment Research Report 2022 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
96 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
Table of Contents
Global Autoimmune Hepatitis Treatment Market Segment Research Report 2022
1. Research Scope
2. Market Overview
2.1 Product Introduction, Application, Picture
2.2 Global Autoimmune Hepatitis Treatment Market by Value
2.2.1 Global Autoimmune Hepatitis Treatment Revenue by Type
2.2.2 Global Autoimmune Hepatitis Treatment Market by Value
2.3 Global Autoimmune Hepatitis Treatment Market by Sales
2.3.1 Global Autoimmune Hepatitis Treatment Sales by Type
2.3.2 Global Autoimmune Hepatitis Treatment Market by Sales
3. The Major Driver of Autoimmune Hepatitis Treatment Industry
3.1 Historical & Forecast Global Autoimmune Hepatitis Treatment Sales and Revenue (2018-2028)
3.2 Largest Application for Autoimmune Hepatitis Treatment (2018-2028)
3.3 The Major Downstream Company in China Market 2022
4. Global and Regional Autoimmune Hepatitis Treatment Market
4.1 Regional Market Size in Terms of Sales (2022 & 2028)
4.2 Regional Market Share in Terms of Revenue (2022 & 2028)
4.3 Concentration Ratio (CR5& CR10) of Autoimmune Hepatitis Treatment Market
4.4 Mergers & Acquisitions, Expansion Plans
5. US Autoimmune Hepatitis Treatment Sales (2018-2028)
5.1 Current and Estimated Sales Breakdown by Type (2018-2028)
5.2 Current and Estimated Sales Breakdown by Application (2018-2028)
5.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
5.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
6. Europe Autoimmune Hepatitis Treatment Sales (2018-2028)
6.1 Current and Estimated Sales Breakdown by Type (2018-2028)
6.2 Current and Estimated Sales Breakdown by Application (2018-2028)
6.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
6.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
7. China Autoimmune Hepatitis Treatment Sales (2018-2028)
7.1 Current and Estimated Sales Breakdown by Type (2018-2028)
7.2 Current and Estimated Sales Breakdown by Application (2018-2028)
7.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
7.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
8. Japan Autoimmune Hepatitis Treatment Sales (2018-2028)
8.1 Current and Estimated Sales Breakdown by Type (2018-2028)
8.2 Current and Estimated Sales Breakdown by Application (2018-2028)
8.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
8.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
9. India Autoimmune Hepatitis Treatment Sales (2018-2028)
9.1 Current and Estimated Sales Breakdown by Type (2018-2028)
9.2 Current and Estimated Sales Breakdown by Application (2018-2028)
9.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
9.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
10. Korea Autoimmune Hepatitis Treatment Sales (2018-2028)
10.1 Current and Estimated Sales Breakdown by Type (2018-2028)
10.2 Current and Estimated Sales Breakdown by Application (2018-2028)
10.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
10.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
11. Southeast Asia Autoimmune Hepatitis Treatment Sales (2018-2028)
11.1 Current and Estimated Sales Breakdown by Type (2018-2028)
11.2 Current and Estimated Sales Breakdown by Application (2018-2028)
11.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
11.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
12. South America Autoimmune Hepatitis Treatment Sales (2018-2028)
12.1 Current and Estimated Sales Breakdown by Type (2018-2028)
12.2 Current and Estimated Sales Breakdown by Application (2018-2028)
12.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
12.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
13. Global Autoimmune Hepatitis Treatment Average Price Trend
13.1 Market Price for Each Type of Autoimmune Hepatitis Treatment in US (2018-2022)
13.2 Market Price for Each Type of Autoimmune Hepatitis Treatment in Europe (2018-2022)
13.3 Market Price for Each Type of Autoimmune Hepatitis Treatment in China (2018-2022)
13.4 Market Price for Each Type of Autoimmune Hepatitis Treatment in Japan (2018-2022)
13.5 Market Price for Each Type of Autoimmune Hepatitis Treatment in India (2018-2022)
13.6 Market Price for Each Type of Autoimmune Hepatitis Treatment in Korea (2018-2022)
13.7 Market Price for Each Type of Autoimmune Hepatitis Treatment in Southeast Asia (2018-2022)
13.8 Market Price for Each Type of Autoimmune Hepatitis Treatment in South America (2018-2022)
14. Industrial Chain (Impact of COVID-19)
14.1 Autoimmune Hepatitis Treatment Industrial Chain Analysis
14.2 Downstream
14.3 Impact of COVID-19
14.4 Post-pandemic Era
14.5 Technology Trends of Autoimmune Hepatitis Treatment
15. Autoimmune Hepatitis Treatment Competitive Landscape
15.1 Gilead Sciences, Inc.
15.1.1 Gilead Sciences, Inc. Company Profiles
15.1.2 Gilead Sciences, Inc. Product Introduction
15.1.3 Gilead Sciences, Inc. Autoimmune Hepatitis Treatment Sales, Revenue (2018-2022)
15.1.4 Strategic initiatives
15.2 Acorda Therapeutics, Inc.
15.2.1 Acorda Therapeutics, Inc. Company Profiles
15.2.2 Acorda Therapeutics, Inc. Product Introduction
15.2.3 Acorda Therapeutics, Inc. Autoimmune Hepatitis Treatment Sales, Revenue (2018-2022)
15.2.4 Strategic initiatives
15.3 Allergan & Novartis
15.3.1 Allergan & Novartis Company Profiles
15.3.2 Allergan & Novartis Product Introduction
15.3.3 Allergan & Novartis Autoimmune Hepatitis Treatment Sales, Revenue (2018-2022)
15.3.4 Strategic initiatives
15.4 Intercept Pharmaceuticals, Inc.
15.4.1 Intercept Pharmaceuticals, Inc. Company Profiles
15.4.2 Intercept Pharmaceuticals, Inc. Product Introduction
15.4.3 Intercept Pharmaceuticals, Inc. Autoimmune Hepatitis Treatment Sales, Revenue (2018-2022)
15.4.4 Strategic initiatives
15.5 Hightidetx
15.5.1 Hightidetx Company Profiles
15.5.2 Hightidetx Product Introduction
15.5.3 Hightidetx Autoimmune Hepatitis Treatment Sales, Revenue (2018-2022)
15.5.4 Strategic initiatives
15.6 Shire Plc.
15.6.1 Shire Plc. Company Profiles
15.6.2 Shire Plc. Product Introduction
15.6.3 Shire Plc. Autoimmune Hepatitis Treatment Sales, Revenue (2018-2022)
15.6.4 Strategic initiatives
15.7 NGM Biopharmaceuticals, Inc.
15.7.1 NGM Biopharmaceuticals, Inc. Company Profiles
15.7.2 NGM Biopharmaceuticals, Inc. Product Introduction
15.7.3 NGM Biopharmaceuticals, Inc. Autoimmune Hepatitis Treatment Sales, Revenue (2018-2022)
15.7.4 Strategic initiatives
15.8 EA Pharma
15.8.1 EA Pharma Company Profiles
15.8.2 EA Pharma Product Introduction
15.8.3 EA Pharma Autoimmune Hepatitis Treatment Sales, Revenue (2018-2022)
15.8.4 Strategic initiatives
15.9 BiomX
15.9.1 BiomX Company Profiles
15.9.2 BiomX Product Introduction
15.9.3 BiomX Autoimmune Hepatitis Treatment Sales, Revenue (2018-2022)
15.9.4 Strategic initiatives
15.10 CymaBay Therapeutics
15.10.1 CymaBay Therapeutics Company Profiles
15.10.2 CymaBay Therapeutics Product Introduction
15.10.3 CymaBay Therapeutics Autoimmune Hepatitis Treatment Sales, Revenue (2018-2022)
15.10.4 Strategic initiatives
15.11 Conatus Pharmaceuticals, Inc.
15.12 Durect Corporation
15.13 Sirnaomics, Inc.
15.14 Shenzhen HighTide Biopharmaceuticals Ltd.
16. Conclusion
17. Methodology and Data Source
LIST OF TABLES & FIGURES
List of Tables and Figures
Figure 1. Total Sales by Application of Autoimmune Hepatitis Treatment Industry (Volume)
Figure 2. Autoimmune Hepatitis Treatment Sales by Regions in 2022
Figure 3. Regional Market Share in Terms of Revenue (2022&2028)
Figure 4. The Top 10 and 5 Players Market Share by Autoimmune Hepatitis Treatment Revenue in 2022
Figure 5. US Autoimmune Hepatitis Treatment Sales (2018-2028)
Figure 6. Sales Breakdown by Type (%)
Figure 7. Sales Breakdown by Type (%)
Figure 8. Sales Breakdown by Application (%)
Figure 9. Revenue Breakdown by Type (%)
Figure 10. Revenue Breakdown by Application (%)
Figure 11. Europe Autoimmune Hepatitis Treatment Sales (2018-2028)
Figure 12. Sales Breakdown by Type (%)
Figure 13. Sales Breakdown by Type (%)
Figure 14. Sales Breakdown by Application (%)
Figure 15. Revenue Breakdown by Type (%)
Figure 16. Revenue Breakdown by Application (%)
Figure 17. China Autoimmune Hepatitis Treatment Sales (2018-2028)
Figure 18. Sales Breakdown by Type (%)
Figure 19. Sales Breakdown by Type (%)
Figure 20. Sales Breakdown by Application (%)
Figure 21. Current and Estimated Revenue Breakdown by Type
Figure 22. Revenue Breakdown by Type (%)
Figure 23. Revenue Breakdown by Application (%)
Figure 24. Japan Autoimmune Hepatitis Treatment Sales (2018-2028)
Figure 25. Sales Breakdown by Type (%)
Figure 26. Sales Breakdown by Type (%)
Figure 27. Sales Breakdown by Application (%)
Figure 28. Revenue Breakdown by Type (%)
Figure 29. Revenue Breakdown by Application (%)
Figure 30. India Autoimmune Hepatitis Treatment Sales (2018-2028)
Figure 31. Sales Breakdown by Type (%)
Figure 32. Sales Breakdown by Type (%)
Figure 33. Sales Breakdown by Application (%)
Figure 34. Revenue Breakdown by Type (%)
Figure 35. Revenue Breakdown by Application (%)
Figure 36. Korea Autoimmune Hepatitis Treatment Sales (2018-2028)
Figure 37. Sales Breakdown by Type (%)
Figure 38. Sales Breakdown by Type (%)
Figure 39. Sales Breakdown by Application (%)
Figure 40. Revenue Breakdown by Type (%)
Figure 41. Revenue Breakdown by Application (%)
Figure 42. Southeast Asia Autoimmune Hepatitis Treatment Sales (2018-2028)
Figure 43. Current and Estimated Sales Breakdown by Type (2018-2028)
Figure 44. Sales Breakdown by Type (%)
Figure 45. Sales Breakdown by Type (%)
Figure 46. Revenue Breakdown by Type (%)
Figure 47. Revenue Breakdown by Application (%)
Figure 48. Industrial Chain
Table 1. Top Manufacturers and Market Segmentation
Table 2. Product Introduction, Application, Picture
Table 3. Autoimmune Hepatitis Treatment Revenue, by Type (Million USD) (2018-2028)
Table 4. Autoimmune Hepatitis Treatment Sales, by Type (K Unit) (2018-2028)
Table 5. Autoimmune Hepatitis Treatment Sales (K Unit) by Application (2018-2028)
Table 6. Autoimmune Hepatitis Treatment Sales (Million USD) by Application (2018-2028)
Table 7. The Major Downstream Company in China
Table 8. Regional Market Share in Terms of Sales (2022)
Table 9. Regional Market Share in Terms of Revenue (2022&2028)
Table 10. Ranking of Global Top Autoimmune Hepatitis Treatment Companies by Revenue, Concentration Ratio in 2022
Table 11. Mergers & Acquisitions, Expansion Plans
Table 12. US Autoimmune Hepatitis Treatment Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 13. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 14. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 15. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 16. Current and Estimated Revenue Breakdown by Type
Table 17. Current and Estimated Revenue Breakdown by Application
Table 18. Europe Autoimmune Hepatitis Treatment Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 19. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 20. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 21. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 22. Current and Estimated Revenue Breakdown by Type
Table 23. Current and Estimated Revenue Breakdown by Application
Table 24. China Autoimmune Hepatitis Treatment Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 25. Table Current and Estimated Sales Breakdown by Type
Table 26. Current and Estimated Sales Breakdown by Type
Table 27. Current and Estimated Sales Breakdown by Application
Table 28. Current and Estimated Revenue Breakdown by Application
Table 29. Japan Autoimmune Hepatitis Treatment Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 30. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 31. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 32. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 33. Current and Estimated Revenue Breakdown by Type
Table 34. Current and Estimated Revenue Breakdown by Application
Table 35. India Autoimmune Hepatitis Treatment Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 36. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 37. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 38. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 39. Current and Estimated Revenue Breakdown by Type
Table 40. Current and Estimated Revenue Breakdown by Application
Table 41. Korea Autoimmune Hepatitis Treatment Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 42. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 43. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 44. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 45. Current and Estimated Revenue Breakdown by Type
Table 46. Current and Estimated Revenue Breakdown by Application
Table 47. Southeast Asia Autoimmune Hepatitis Treatment Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 48. Table Current and Estimated Sales Breakdown by Type (2018-2028)
Table 49. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 50. Current and Estimated Revenue Breakdown by Type
Table 51. Current and Estimated Revenue Breakdown by Application
Table 52. Market Price (USD/Unit) for Each Type of Autoimmune Hepatitis Treatment in US (2018-2022)
Table 53. Market Price (USD/Unit) for Each Type of Autoimmune Hepatitis Treatment in Europe (2018-2022)
Table 54. Market Price (USD/Unit) for Each Type of Autoimmune Hepatitis Treatment in China (2018-2022)
Table 55. Market Price (USD/Unit) for Each Type of Autoimmune Hepatitis Treatment in Japan (2018-2022)
Table 56. Market Price (USD/Unit) for Each Type of Autoimmune Hepatitis Treatment in India (2018-2022)
Table 57. Market Price (USD/Unit) for Each Type of Autoimmune Hepatitis Treatment in Korea (2018-2022)
Table 58. Market Price (USD/Unit) for Each Type of Autoimmune Hepatitis Treatment in Southeast Asia (2018-2022)
Table 59. Key Downstream Customer in Each Application Field
Table 60. Gilead Sciences, Inc. Profiles
Table 61. Gilead Sciences, Inc. Autoimmune Hepatitis Treatment Product Introduction
Table 62. Gilead Sciences, Inc. Autoimmune Hepatitis Treatment Sales (Unit), Revenue (Million USD) (2018-2022)
Table 63. Gilead Sciences, Inc. Strategic initiatives
Table 64. Acorda Therapeutics, Inc. Profiles
Table 65. Acorda Therapeutics, Inc. Autoimmune Hepatitis Treatment Product Introduction
Table 66. Acorda Therapeutics, Inc. Autoimmune Hepatitis Treatment Sales (Unit), Revenue (Million USD) (2018-2022)
Table 67. Acorda Therapeutics, Inc. Strategic initiatives
Table 68. Allergan & Novartis Profiles
Table 69. Allergan & Novartis Autoimmune Hepatitis Treatment Product Introduction
Table 70. Allergan & Novartis Autoimmune Hepatitis Treatment Sales (Unit), Revenue (Million USD) (2018-2022)
Table 71. Allergan & Novartis Strategic initiatives
Table 72. Intercept Pharmaceuticals, Inc. Profiles
Table 73. Intercept Pharmaceuticals, Inc. Autoimmune Hepatitis Treatment Product Introduction
Table 74. Intercept Pharmaceuticals, Inc. Autoimmune Hepatitis Treatment Sales (Unit), Revenue (Million USD) (2018-2022)
Table 75. Intercept Pharmaceuticals, Inc. Strategic initiatives
Table 76. Hightidetx Profiles
Table 77. Hightidetx Autoimmune Hepatitis Treatment Product Introduction
Table 78. Hightidetx Autoimmune Hepatitis Treatment Sales (Unit), Revenue (Million USD) (2018-2022)
Table 79. Hightidetx Strategic initiatives
Table 80. Shire Plc. Profiles
Table 81. Shire Plc. Autoimmune Hepatitis Treatment Product Introduction
Table 82. Shire Plc. Autoimmune Hepatitis Treatment Sales (Unit), Revenue (Million USD) (2018-2022)
Table 83. Shire Plc. Strategic initiatives
Table 84. NGM Biopharmaceuticals, Inc. Profiles
Table 85. NGM Biopharmaceuticals, Inc. Autoimmune Hepatitis Treatment Product Introduction
Table 86. NGM Biopharmaceuticals, Inc. Autoimmune Hepatitis Treatment Sales (Unit), Revenue (Million USD) (2018-2022)
Table 87. NGM Biopharmaceuticals, Inc. Strategic initiatives
Table 88. EA Pharma Profiles
Table 89. EA Pharma Autoimmune Hepatitis Treatment Product Introduction
Table 90. EA Pharma Autoimmune Hepatitis Treatment Sales (Unit), Revenue (Million USD) (2018-2022)
Table 91. EA Pharma Strategic initiatives
Table 92. BiomX Profiles
Table 93. BiomX Autoimmune Hepatitis Treatment Product Introduction
Table 94. BiomX Autoimmune Hepatitis Treatment Sales (Unit), Revenue (Million USD) (2018-2022)
Table 95. BiomX Strategic initiatives
Table 97. CymaBay Therapeutics Profiles
Table 98. CymaBay Therapeutics Autoimmune Hepatitis Treatment Product Introduction
Table 99. CymaBay Therapeutics Autoimmune Hepatitis Treatment Sales (Unit), Revenue (Million USD) (2018-2022)
Table 100. CymaBay Therapeutics Strategic initiatives
Table 101. Conatus Pharmaceuticals, Inc. Profiles
Table 102. Conatus Pharmaceuticals, Inc. Autoimmune Hepatitis Treatment Product Introduction
Table 103. Conatus Pharmaceuticals, Inc. Autoimmune Hepatitis Treatment Sales (Unit), Revenue (Million USD) (2018-2022)
Table 104. Conatus Pharmaceuticals, Inc. Strategic initiatives
Table 105. Durect Corporation Profiles
Table 106. Durect Corporation Autoimmune Hepatitis Treatment Product Introduction
Table 107. Durect Corporation Autoimmune Hepatitis Treatment Sales (Unit), Revenue (Million USD) (2018-2022)
Table 108. Durect Corporation Strategic initiatives
Table 109. Sirnaomics, Inc. Profiles
Table 110. Sirnaomics, Inc. Autoimmune Hepatitis Treatment Product Introduction
Table 111. Sirnaomics, Inc. Autoimmune Hepatitis Treatment Sales (Unit), Revenue (Million USD) (2018-2022)
Table 112. Sirnaomics, Inc. Strategic initiatives
Table 113. Shenzhen HighTide Biopharmaceuticals Ltd. Profiles
Table 114. Shenzhen HighTide Biopharmaceuticals Ltd. Autoimmune Hepatitis Treatment Product Introduction
Table 115. Shenzhen HighTide Biopharmaceuticals Ltd. Autoimmune Hepatitis Treatment Sales (Unit), Revenue (Million USD) (2018-2022)
Table 116. Shenzhen HighTide Biopharmaceuticals Ltd. Strategic initiatives
